|
|
|||
Immunogenic sites on anti-TNF drugsHuman TNFRp75 (TNFRII) fusion protein (etanercept) |
|||
 |
|||
|
Even though the molecule consists of 100% human sequences, T- and B-cells may recognize peptide fragments overlapping the region between the two human parts as non-self and, hence, raise specific immune responses to the drug.
Anti-allotypic responses may also contribute to drug immunogenicity. |
|||